Abcam Share Discussion Threads

[sunningdale1] 30/9/2019 13:42

#136

ORPH looks promising to say the least - The new management team has a track record of building successful business and Open Orphan has a clear four pronged growth strategy. The market Open Orphan is targeting is one of the fastest growing in the drug sector with political support behind it and under-supply of treatments for orphan drugs.

The end market for Open Orphan is the growing orphan/ rare drug market and the need for consultancy services, particularly in Europe, to launch these products. The orphan drug sector is one of the fastest growing sectors in the global pharmaceutical industry and in the US in 2018 over 50% of all new US Food and Drug Administration approved drugs coming to market are for rare/orphan conditions. In Europe, 57% of all new drugs are orphan designated and globally the orphan/ rare drug market is growing at twice (11%) the pace of the global pharma market

[lenzcrafter] 30/9/2019 13:16

Stumbling!

[fp optimist] 27/9/2019 08:34

jbfnfn,I agree in the importance of the impairment cost. I had assumed that Abcam were earlier indicating that they were about to tidy up their core business with the acquisition of Horizon, but have been pulled back on that because of the need first to come clean on their dreadful ERP programme (I thought it started with SAP!) and to get rid of their FD.

[bathcoup] 27/9/2019 08:31

#135
I didn't spell it out in #133 but you've analysed the issue better than I could. Oracle products are very bad; they're for governments, inefficient corporations ...

[cokehookerscars] 27/9/2019 01:01

"CEO Cathal Friel predicts 40% growth a year" !!

That's seriously high. How much confidence does anyone have in that ??

[jbfnfn] 26/9/2019 19:59

#133

From the Final results

"Enterprise Resource Planning (ERP) programme
.
.
As a result of the changes in the scope and nature of the programme and the usability of historical work performed, software development costs capitalised to date of £12.8m, have been impaired."

They capitalised money spent on software and now they have written it off. You can argue that they should never have capitalised it in the first place. A business like this must have scalable top notch IT. They are always going to be spending on IT. It's an expense it shouldn't be capitalised. Have they made a mistake using Oracle for their ERP? It sounds like they have. At least they have realised it and are doing something about it. They should have, or certainly need a strong internal IT ability.

[sunningdale1] 26/9/2019 13:10

Recently added - great to see ABC bouncing back over the last two days. Open Orphan AIM:ORPH a stock definitely worth keeping tabs on - Rises today and CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. They are currently on a presenting roadshow if anyone is interested hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

[bathcoup] 11/9/2019 15:37

"GBP12.8 million impairment charge associated with its Oracle Cloud Enterprise Resource Planning programme"
How stupid!

[buywell3] 10/9/2019 11:25

abc share price imo at bottom support line as i key

dyor

[mw8156] 10/9/2019 11:23

significant fall in the share price might result in it being taken over as the leading antibody company, their cash generative nature and their huge catalogue of 18000 validated antibodies and that would be Britain's only leading life sciences tools company disappearing which would be a shame after Illumina snapped up our sequencing technology.

[lenzcrafter] 09/9/2019 19:43

And you can bet your bottom dollar it bounces tomorrow by nearly what it's has fell by today.

[lenzcrafter] 09/9/2019 08:52

It's simple...it always drops on good news! Done

[buywell3] 09/9/2019 08:48

It is very easy to be wise after the event

but buywell sees many before they happen cos he is good at charting see




buywell3 9 Jun '19 - 10:43 - 106 of 114 Edit

Just to give you guys something to chew one ... the bear case

The Chart does stand at a point at which I feel a previous top is being tested

IF it fails say due to macro market issues

The bottom support suggests 1150p could be tested in a timescale of approx 1 to 2 months based upon the last decent drop.



dyor

[buywell3] 09/9/2019 07:20

IMO it all comes down to these reported hree numbers in brackets which indicate a loss



year ............. 2018/19 2017/18

Operating profit 56.1 68.8 (18.5)%
Profit Before Tax (PBT) 56.4 69.1 (18.4)%
Diluted earnings per share (EPS) (pence) 21.8p 30.2p (27.8)%

[lenzcrafter] 09/9/2019 07:04

You watch this bomb today.

[lenzcrafter] 15/8/2019 15:29

I'm feeling this is a little weak at the moment. Shame as it was on a bit of a climb for the last few months.

[ifthecapfits] 09/8/2019 08:40

Back in FWIW. Higher Highs, lower lows, and bounced of 12. All looks good to me.

[smokybenchod] 23/7/2019 22:37

He’s too busy spouting nonesense on the Fevertree board.

[phillis] 23/7/2019 13:15

buywell

Comments on your position?

[lenzcrafter] 23/7/2019 08:19

Boing! Just as expected

[lenzcrafter] 22/7/2019 17:15

You watch it bounce tomorrow. 140 up I bet!

[smokybenchod] 22/7/2019 17:09

The broker note is from Peel Hunt and widely reported outside of proactive on other website such as FT etc.

[phillis] 22/7/2019 16:15

who pays attention to proactive investors